Crescent Biopharma (CBIO) Q3 FY2026 earnings: revenue $3 million
Crescent Biopharma, Inc. (CBIO) reported revenue of $3 million for Q3 FY2026, the quarter ended 30 September 2026. Net income was -$38 million. The figures are the company's own, from the 10-Q it filed with the SEC on 12 November 2026.
this quarterthe same quarter a year earlierHover a bar for its figure.
Income statement (profit and loss)
| $ million | Q3 FY2026 | Q2 FY2026 | Q3 FY2025 | On the quarter | On the year | Last 8 quarters |
|---|---|---|---|---|---|---|
| Revenue | 3.1 | 0.0 | 0.0 | |||
| Research and development | 34.3 | 19.4 | 20.3 | +76.9% | +68.6% | |
| Operating income | -39.9 | -26.4 | -25.9 | |||
| Operating margin | -1280.3% | n/a | n/a | |||
| Interest expense | 0.0 | 0.0 | 0.0 | |||
| Income tax | 0.0 | 0.0 | 0.0 | |||
| Net income | -37.7 | -24.8 | -24.6 | |||
| Net margin | -1210.3% | n/a | n/a |
$ million except per share.
Read more
Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.Cash flow
| $ million | Q3 FY2026 | Q2 FY2026 | Q3 FY2025 | On the quarter | On the year | Last 8 quarters |
|---|---|---|---|---|---|---|
| Operating cash flow | -26.9 | -19.5 | -17.5 | |||
| Capital expenditure | 0.0 | 0.0 | 0.6 | |||
| Free cash flow | -26.9 | -19.5 | -18.1 | |||
| Free cash flow margin | -864.2% | n/a | n/a | |||
| Cash from investing | 0.0 | 1.8 | -0.6 | |||
| Cash from financing | 145 | 0.1 | -1.3 | +106,380.1% | ||
| Depreciation | 0.1 | 0.1 | 0.0 | +1.5% | +139.3% | |
| Share-based compensation | 4.2 | 4.0 | 2.0 | +6.4% | +112.6% | |
| Shares outstanding at period end | 38m | 28m | 14m | +37.6% | +174.8% |
Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.
Balance sheet
| $ million | Q3 FY2026 | Q2 FY2026 | Q3 FY2025 | On the quarter | On the year | Last 8 quarters |
|---|---|---|---|---|---|---|
| Shareholders' equity | 274 | 163 | 117 | +68.0% | +135.1% | |
| Debt | 0.0 | 0.0 | 0.0 | |||
| Operating lease liabilities | 1.7 | 1.0 | 1.3 | +79.5% | +31.0% | |
| Other liabilities | 23.5 | 18.5 | 20.3 | +26.7% | +15.7% | |
| Total liabilities and equity | 300 | 183 | 138 | +63.9% | +116.6% | |
| Fixed assets | 0.8 | 0.9 | 0.8 | -7.6% | +3.5% | |
| Cash and equivalents | 289 | 172 | 133 | +68.6% | +117.1% | |
| Receivables | 0.0 | 0.0 | n/a | |||
| Other assets | 9.3 | 10.3 | 4.2 | -9.3% | +121.2% | |
| Total assets | 300 | 183 | 138 | +63.9% | +116.6% |
Questions
What was Crescent Biopharma's revenue in Q3 FY2026?
Crescent Biopharma (CBIO) reported revenue of $3 million for Q3 FY2026, the quarter ended 30 September 2026.
How much did Crescent Biopharma earn in Q3 FY2026?
Net loss for Q3 FY2026 was $38 million.
When did Crescent Biopharma report Q3 FY2026 results?
Crescent Biopharma filed its 10-Q for the quarter ended 30 September 2026 with the SEC on 12 November 2026.
Quarterly results, the last 8 quarters
| Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 * | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 10.8 | 1.0 | 0.0 | 3.1 |
| R&D | 14.0 | 10.6 | 12.1 | 20.3 | 95.0 | 17.9 | 19.4 | 34.3 |
| Operating income | -17.2 | -14.2 | -21.0 | -25.9 | -91.5 | -24.7 | -26.4 | -39.9 |
| Operating margin | n/a | n/a | n/a | n/a | -844% | -2380% | n/a | -1280% |
| Interest expense | 0.9 | 1.1 | 1.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Pre-tax income | -17.9 | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Net income | -17.9 | -15.1 | -21.8 | -24.6 | -23.3 | -23.3 | -24.8 | -37.7 |
| Net margin | n/a | n/a | n/a | n/a | -215% | -2241% | n/a | -1210% |
| Operating cash flow | -6.3 | -10.9 | -16.4 | -17.5 | -26.7 | -8.9 | -19.5 | -26.9 |
| Capital expenditure | 0.0 | 0.0 | 0.1 | 0.6 | 0.2 | 0.1 | 0.0 | 0.0 |
| Free cash flow | -6.3 | -10.9 | -16.5 | -18.1 | -26.9 | -9.1 | -19.5 | -26.9 |
| Shares outstanding | 1m | 28m | 14m | 14m | 28m | 28m | 28m | 38m |
| Filing | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q |
Each quarter as filed, linked to its filing.
Read more
* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.10-Q for the period ended 30 September 2026, filed 12 November 2026: the filing.